Phase Ii trial of mitolactol in patients with metastatic melanoma
Medina, W.; Kirkwood, J.M.
Cancer Treatment Reports 66(1): 195-196
1982
ISSN/ISBN: 0361-5960 PMID: 7053257 Document Number: 185836
Document emailed within 1 workday
Related Documents
Nemunaitis, J.; Bohart, C.; Fong, T.; Meyer, W.; Edelman, G.; Paulson, R.S.; Orr, D.; Jain, V.; O'Brien, J.; Kuhn, J.; Kowal, K.J.; Burkeholder, S.; Bruce, J.; Ognoskie, N.; Wynne, D.; Martineau, D.; Ando, D. 1998: Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma Cancer Gene Therapy 5(5): 292-300Creech, R.H.; Catalano, R.B.; Dierks, K.M.; Shah, M.K. 1984: Phase Ii study of mitolactol in chemotherapy-refractory metastatic breast cancer Cancer Treatment Reports 68(12): 1499-1501
Creagan, E.T.; Ahmann, D.L.; Schutt, A.J.; Green, S.J. 1982: Phase Ii study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma Cancer Treatment Reports 66(6): 1425-1426
Thigpen, J.T.; Al-Sarraf, M.; Hewlett, J.S. 1979: Phase Ii trial of dianhydrogalactitol in metastatic malignant melanoma: a Southwest Oncology Group study Cancer Treatment Reports 63(4): 525-528
Yamaguchi, Y.; Minami, K.; Kawabuchi, Y.; Emi, M. 2006: A phase I trial of CPT-11 in combination with 5-fluorouracil plus leucovorin chemotherapy for patients with metastatic colorectal cancer Hepato-Gastroenterology 53(68): 201-205
Debruyne, F.M.; Karthaus, H.F.; Schröder, F.H.; de Voogt, H.J.; de Jong, F.H.; Klijn, J.G. 1985: Results of a Dutch Phase Ii trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer Progress in Clinical and Biological Research 185a: 251-270
Gravis, G.; Mousseau, M.; Douillard, J.Y.; Dorval, T.; Fabbro, M.; Escudier, B.; Mignot, L.; Viens, P. 2001: Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trial European Cytokine Network 12(2): 239-243
Muthalib, A.; Darwis, I.; Prayogo, N.; Sutjipto 2000: Preliminary results of multicenter phase Ii trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(Suppl 2): 498-504
Carmichael, J.; Atkinson, R.J.; Calman, K.C.; Mackie, R.M.; Naysmith, A.M.; Smyth, J.F. 1982: A multicentre phase II trial of vindesine in malignant melanoma European Journal of Cancer and Clinical Oncology 18(12): 1293-1295
Proebstle, T.M.; Scheibenbogen, C.; Sterry, W.; Keilholz, U. 1996: A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma European Journal of Cancer 32a(9): 1530-1533
Bukowski, R.M.; Sergi, J.S.; Sharfman, W.J.; Budd, G.T.; Murthy, S.; Barna, B.; Medendorp, S.V.; Yen-Lieberman, B.; Gibson, V.; Bauer, L. 1991: Phase i trial of natural human interferon beta in metastatic malignancy Cancer Research 51(3): 836-840
Bonomi, P.D.; Pazdur, R.; Stolbach, L.; Mason, B.; Ettinger, D. 1986: Phase Ii trial of mitomycin, vindesine, and hexamethylmelamine in metastatic non-small cell bronchogenic carcinoma Cancer Treatment Reports 70(12): 1447-1448
Herlyn, M.; Balaban, G.; Bennicelli, J.; Guerry, D.; Halaban, R.; Herlyn, D.; Elder, D.E.; Maul, G.G.; Steplewski, Z.; Nowell, P.C. 1985: Primary melanoma cells of the vertical growth phase: similarities to metastatic cells Journal of the National Cancer Institute 74(2): 283-289
Carpenter, J.T.; Raney, M.; Logan, T. 1986: Phase Ii evaluation of procarbazine in metastatic breast cancer: a Southeastern Cancer Study Group Trial Cancer Treatment Reports 70(5): 679-680
Nicholson, B.; Paul, D.; Shyr, Y.; Garrett, M.; Hande, K.R.; Johnson, D.H. 1997: Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase Ii trial Seminars in Oncology 24(4 Suppl 11: S11
Locker, G.Y.; Khandekar, J.; Krauss, S.; Reisel, H.; Hoeltgen, T.; Wolter, J.; Haid, M.; Hoffman, R.; Blough, R.; Johnson, C. 1987: Phase II trial of aminothiadiazole in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial Cancer Treatment Reports 71(6): 649-650
Dutcher, J.P. 2011: High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard Oncology 25(5): 427-428
Saha, S.; Mohanty, K.C. 2003: Enhancement of metastatic potential of mouse B16-melanoma cells to lung after treatment with gangliosides of B-16-melanoma cells of higher metastatic potential to lung Indian Journal of Experimental Biology 41(11): 1253-1258
Fløe, L.E.ær.; Svane, I.M.; Bastholt, L.; Schmidt, H. 2016: Immune checkpoint antibodies increase survival in patients with metastatic melanoma Ugeskrift for Laeger 178(33)
Royal, R.E.; Steinberg, S.M.; Krouse, R.S.; Heywood, G.; White, D.E.; Hwu, P.; Marincola, F.M.; Parkinson, D.R.; Schwartzentruber, D.J.; Topalian, S.L.; Yang, J.C.; Rosenberg, S.A. 1996: Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma Cancer Journal from Scientific American 2(2): 91-98